Change in Preferred Drug List (PDL) Status for Beta Agonist Drug Class

Date: January 13, 2025

Attention: All Providers

Effective date: January 3, 2025

Call to action: Effective January 3, 2025, generic Levalbuterol inhalation solution will now be preferred. This is in response to discontinuation of brand product Xopenex by the manufacturer.

The preferred status of the brand name Xopenex will not change to allow any remaining stock to be used.

How this impacts providers: The change will allow providers to prescribe the generic without requiring preferred drug list (PDL) prior authorization at this time and continue accessing necessary medication for their patients.

Next step for providers: Prescribers are encouraged to proactively obtain a prescription for the preferred alternatives to avoid disruption in patient’s therapy. Prescribers should share this communication with their staff.

If you have any questions, please email TCHP Pharmacy at: tchppharmacy@texaschildrens.org

For access to all provider alerts, log into: www.texaschildrenshealthplan.org/provideralerts